Immunoreactivity with the Anti-MAGE Antibody 57B in Malignant Melanoma: Frequency of Expression and Correlation with Prognostic Parameters

[1]  C. Figdor,et al.  Genomic organization, chromosomal localization, and 5′ upstream region of the human DC-STAMP gene , 2001, Immunogenetics.

[2]  Yao-Tseng Chen,et al.  Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies , 1998, International journal of cancer.

[3]  Yao-Tseng Chen,et al.  Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. , 1998, The American journal of surgical pathology.

[4]  P. Dalerba,et al.  High homogeneity of MAGE, BAGE, GAGE, Tyrosinase and Melan‐A/MART‐1 gene expression in clusters of multiple simultaneous metastases of human melanoma: Implications for protocol design of therapeutic antigen‐specific vaccination strategies , 1998, International journal of cancer.

[5]  Yao-Tseng Chen,et al.  Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  W. Gerald,et al.  A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. , 1998, The American journal of surgical pathology.

[7]  E. Kremmer,et al.  MAGE‐11 protein is highly conserved in higher organisms and located predominantly in the nucleus , 1998, International journal of cancer.

[8]  K. Arden,et al.  Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. , 1998, Cancer research.

[9]  R. Dummer,et al.  MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. , 1997, The American journal of pathology.

[10]  L. Old,et al.  Cancer Tumor antigens. , 1997, Current opinion in immunology.

[11]  D. Cole,et al.  Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. , 1996, Seminars in oncology.

[12]  L. Hakansson,et al.  Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. , 1996, British Journal of Cancer.

[13]  K. Mimori,et al.  Expression of MAGE genes in human colorectal carcinoma. , 1996, Annals of surgery.

[14]  Yao-Tseng Chen,et al.  Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Mihm,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[16]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[17]  J. Kirkwood,et al.  New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines , 1996, Melanoma research.

[18]  N. Cascinelli,et al.  Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.

[19]  Rika Deraemaecker,et al.  Expression of MAGE genes in primary and metastatic cutaneous melanoma , 1995, International journal of cancer.

[20]  A. Amoroso,et al.  Peptide‐specific ctl in tumor‐infiltrating lymphocytes from metastatic melanomas expressing mart‐1/melan‐a, gp100 and tyrosinase genes: A study in an unselected group of hla‐a2.1‐positive patients , 1995, International journal of cancer.

[21]  O. de Backer,et al.  A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma , 1995, The Journal of experimental medicine.

[22]  Yao-Tseng Chen,et al.  Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  F. Gudat,et al.  Identification and intracellular location of MAGE-3 gene product. , 1995, Cancer research.

[24]  J. Renauld,et al.  Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes , 1995, Immunological reviews.

[25]  J. Patard,et al.  Expression of mage genes in transitional‐cell carcinomas of the urinary bladder , 1995, International journal of cancer.

[26]  P. Coulie,et al.  A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3 , 1994, European journal of immunology.

[27]  F. Brasseur,et al.  Expression of mage genes by non‐small‐cell lung carcinomas , 1994, International journal of cancer.

[28]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[29]  Max H. Myers,et al.  Manual for Staging of Cancer , 1992 .

[30]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[31]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[32]  W. Clark,et al.  The biologic forms of malignant melanoma. , 1986, Human pathology.

[33]  W. Clark,et al.  The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51—3.99 mm) , 1985, Cancer.

[34]  M. Hansen,et al.  Tumor thickness and lymphocytic infiltration in malignant melanoma of the head and neck. , 1974, American journal of surgery.

[35]  W. Clark,et al.  The classification of malignant melanoma and its histologic reporting , 1973, Cancer.

[36]  A Breslow,et al.  Thickness, Cross‐Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma , 1970, Annals of surgery.

[37]  Harlan I. Firminger,et al.  Atlas of tumor pathology , 1954 .

[38]  Yao-Tseng Chen,et al.  Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. , 1998, The American journal of surgical pathology.

[39]  M. Mihm,et al.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[40]  S. Rosenberg,et al.  The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. , 1996, Annual review of medicine.

[41]  M. Arlen.  Tumor antigens. , 1981, The New England journal of medicine.